Innoviva Yönetim

Yönetim kriter kontrolleri 4/4

Innoviva's CEO is Pavel Raifeld, appointed in May 2020, has a tenure of 4.5 years. total yearly compensation is $868.65K, comprised of 55.8% salary and 44.2% bonuses, including company stock and options. directly owns 0.019% of the company’s shares, worth $224.72K. The average tenure of the management team and the board of directors is 2.9 years and 6.8 years respectively.

Anahtar bilgiler

Pavel Raifeld

İcra Kurulu Başkanı

US$868.6k

Toplam tazminat

CEO maaş yüzdesi55.8%
CEO görev süresi4.5yrs
CEO sahipliği0.02%
Yönetim ortalama görev süresi2.9yrs
Yönetim Kurulu ortalama görev süresi6.8yrs

Son yönetim güncellemeleri

Recent updates

Benign Growth For Innoviva, Inc. (NASDAQ:INVA) Underpins Its Share Price

Jul 26
Benign Growth For Innoviva, Inc. (NASDAQ:INVA) Underpins Its Share Price

Innoviva: Potentially Overvalued

Jun 21

Why Innoviva's (NASDAQ:INVA) Shaky Earnings Are Just The Beginning Of Its Problems

May 21
Why Innoviva's (NASDAQ:INVA) Shaky Earnings Are Just The Beginning Of Its Problems

Here's Why Innoviva (NASDAQ:INVA) Can Manage Its Debt Responsibly

Feb 05
Here's Why Innoviva (NASDAQ:INVA) Can Manage Its Debt Responsibly

Is Innoviva (NASDAQ:INVA) A Risky Investment?

Nov 04
Is Innoviva (NASDAQ:INVA) A Risky Investment?

Innoviva (NASDAQ:INVA) Seems To Use Debt Quite Sensibly

Mar 02
Innoviva (NASDAQ:INVA) Seems To Use Debt Quite Sensibly

Innoviva Stock? Not Yet. Short Puts? Definitely.

Sep 19

Does Innoviva (NASDAQ:INVA) Have A Healthy Balance Sheet?

Sep 19
Does Innoviva (NASDAQ:INVA) Have A Healthy Balance Sheet?

Does Innoviva (NASDAQ:INVA) Have A Healthy Balance Sheet?

Jun 16
Does Innoviva (NASDAQ:INVA) Have A Healthy Balance Sheet?

Continuing To Avoid Innoviva Inc.

Jun 07

We Think Innoviva (NASDAQ:INVA) Can Manage Its Debt With Ease

Mar 04
We Think Innoviva (NASDAQ:INVA) Can Manage Its Debt With Ease

Taking Innoviva Winnings Off The Table, Again

Feb 21

Innoviva Inc.: Short Puts Are Compelling

Jan 15

Is Innoviva (NASDAQ:INVA) A Risky Investment?

Oct 19
Is Innoviva (NASDAQ:INVA) A Risky Investment?

Taking Profits In Innoviva Inc.

Oct 16

Innoviva reports Q1 results

Apr 28

These 4 Measures Indicate That Innoviva (NASDAQ:INVA) Is Using Debt Safely

Mar 30
These 4 Measures Indicate That Innoviva (NASDAQ:INVA) Is Using Debt Safely

Is Weakness In Innoviva, Inc. (NASDAQ:INVA) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?

Mar 04
Is Weakness In Innoviva, Inc. (NASDAQ:INVA) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?

Did Innoviva's (NASDAQ:INVA) Share Price Deserve to Gain 36%?

Jan 15
Did Innoviva's (NASDAQ:INVA) Share Price Deserve to Gain 36%?

These 4 Measures Indicate That Innoviva (NASDAQ:INVA) Is Using Debt Safely

Dec 25
These 4 Measures Indicate That Innoviva (NASDAQ:INVA) Is Using Debt Safely

Will Weakness in Innoviva, Inc.'s (NASDAQ:INVA) Stock Prove Temporary Given Strong Fundamentals?

Dec 04
Will Weakness in Innoviva, Inc.'s (NASDAQ:INVA) Stock Prove Temporary Given Strong Fundamentals?

Innoviva: Only For Short-Term Traders

Nov 04

Innoviva reports Q3 results

Oct 28

CEO Tazminat Analizi

Pavel Raifeld'un ücretlendirmesi Innoviva'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Jun 30 2024n/an/a

US$145m

Mar 31 2024n/an/a

US$181m

Dec 31 2023US$869kUS$485k

US$180m

Sep 30 2023n/an/a

US$50m

Jun 30 2023n/an/a

US$233m

Mar 31 2023n/an/a

US$233m

Dec 31 2022US$2mUS$440k

US$214m

Sep 30 2022n/an/a

US$293m

Jun 30 2022n/an/a

US$99m

Mar 31 2022n/an/a

US$188m

Dec 31 2021US$1mUS$391k

US$266m

Sep 30 2021n/an/a

US$309m

Jun 30 2021n/an/a

US$265m

Mar 31 2021n/an/a

US$253m

Dec 31 2020US$2mUS$222k

US$224m

Tazminat ve Piyasa: Pavel's total compensation ($USD868.65K) is below average for companies of similar size in the US market ($USD5.64M).

Tazminat ve Kazançlar: Pavel's compensation has been consistent with company performance over the past year.


CEO

Pavel Raifeld (40 yo)

4.5yrs

Görev süresi

US$868,648

Tazminat

Mr. Pavel Raifeld, CFA, is Director of La Jolla Pharmaceutical Company since August 22, 2022. He serves as Chief Executive Officer of Innoviva, Inc. since May 2020. He is a seasoned healthcare executive wi...


Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Pavel Raifeld
Chief Executive Officer4.5yrsUS$868.65k0.019%
$ 224.7k
Stephen Basso
Chief Financial Officer1.3yrsUS$1.18mVeri yok
Marianne Zhen
Chief Accounting Officer & Secretary6.3yrsUS$924.21k0.073%
$ 878.5k
Patricia Drake
Chief Commercial Officer-Innoviva Specialty Therapeuticsless than a yearVeri yokVeri yok

2.9yrs

Ortalama Görev Süresi

56.5yo

Ortalama Yaş

Deneyimli Yönetim: INVA's management team is considered experienced (2.9 years average tenure).


Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Jules Haimovitz
Independent Director6.8yrsUS$446.02k0.19%
$ 2.3m
Sapna Srivastava
Independent Director1.8yrsUS$547.11k0.041%
$ 490.3k
Derek Small
Independent Directorless than a yearVeri yokVeri yok
Odysseas Kostas
Independent Director6.9yrsUS$331.18k0.17%
$ 2.1m
Sarah Schlesinger
Independent Director6.8yrsUS$367.25k0.17%
$ 2.0m
Mark DiPaolo
Independent Director6.8yrsUS$396.59k0.17%
$ 2.0m

6.8yrs

Ortalama Görev Süresi

52.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: INVA's board of directors are considered experienced (6.8 years average tenure).